Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
+ 329 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 271 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 115 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Locations: - Investigative Site US058 — Birmingham, Alabama
- Investigative Site US016 — Anchorage, Alaska
- Investigative Site US026 — Chandler, Arizona
+ 67 more sites in the U.S.
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Locations: - University of Arizona Cancer Center - North Campus — Tucson, Arizona
- Mercy Cancer Center — Fort Smith, Arkansas
- Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
+ 46 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Locations: - The University of Alabama at Birmingham — Birmingham, Alabama
- Mayo Clinic Hospital — Phoenix, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
+ 37 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- City of Hope — Phoenix, Arizona
- City of Hope — Duarte, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Locations: - VA Loma Linda Healthcare System — Loma Linda, California
- Sutter Cancer Center Sacramento — Sacramento, California
- Rocky Mountain Cancer Centers — Denver, Colorado
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
+ 14 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Locations: - Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas
- Providence Medical Foundation — Fullerton, California
- Yale Cancer Center — New Haven, Connecticut
+ 11 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Locations: - Investigative Site — Chicago, Illinois
- Investigative Site — Bethesda, Maryland
- Investigative Site — Boston, Massachusetts
+ 5 more sites in the U.S.